Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | Phase 1 | terminated | Aug 29, 2019 | Klinikum Stuttgart | low recruitment | Enrollment / accrual |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | Phase 1 / Phase 2 | terminated | Sep 20, 2019 | AGC Biologics S.p.A. | Inability to close the study in a clinically relevant time frame | Other (stated, no rule matched) |
| NCT00384111 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular… | Phase 3 | terminated | Oct 5, 2006 | Spectrum Pharmaceuticals, Inc | Study was terminated early as per the Sponsor's decision. | Sponsor / business decision |
| NCT02589860 | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous… | — | withdrawn | Oct 28, 2015 | Sherif S. Farag | No accrual | Enrollment / accrual |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | Phase 1 | terminated | Nov 25, 2019 | The First Affiliated Hospital with Nanjing Medical University | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT01510184 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly… | Phase 3 | terminated | Jan 13, 2012 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen… | Phase 2 | terminated | May 17, 2019 | Jazz Pharmaceuticals | Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20… | Efficacy / futility |
| NCT03135262 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants… | Phase 1 / Phase 2 | terminated | May 1, 2017 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed…(COAST) | Phase 1 | withdrawn | Jun 9, 2021 | Oncopeptides AB | Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program. | Other (stated, no rule matched) |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | Phase 1 | withdrawn | Aug 21, 2018 | Virginia Commonwealth University | Slow Accrual | Enrollment / accrual |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With… | Phase 2 | terminated | May 28, 2007 | Rush University Medical Center | Lack of accrual and interest in study | Enrollment / accrual |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse… | Phase 1 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | In a limited number of patients, no additional activity was evident for the combination vs.… | Other (stated, no rule matched) |
| NCT00256776 | MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous… | Phase 3 | terminated | Nov 22, 2005 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT03537222 | Quality of Life in Patients With Multiple Myeloma-validation Study | — | terminated | May 25, 2018 | Zurich University of Applied Sciences | Not enough participants and study funding | Funding |
| NCT02840110 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | — | terminated | Jul 21, 2016 | Cogent Biosciences, Inc. | Business Decision | Sponsor / business decision |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475)… | Phase 3 | terminated | Oct 15, 2015 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons | Sponsor / business decision |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | Phase 3 | terminated | Aug 10, 2012 | Spectrum Pharmaceuticals, Inc | Sponsor decision | Sponsor / business decision |
| NCT03585725 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and… | Early Phase 1 | terminated | Jul 13, 2018 | Weill Medical College of Cornell University | low accrual | Enrollment / accrual |
| NCT02394210 | Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma(EPA-MMBR) | — | terminated | Mar 20, 2015 | Celgene | Bias in the study | Other (stated, no rule matched) |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | Phase 2 | terminated | Jan 11, 2010 | University of Liege | recruitment too slow | Enrollment / accrual |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second…(Immuno-POWER) | Phase 2 | withdrawn | Oct 12, 2020 | Natalie Callendar | Funder pulled support/funding | Funding |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Jun 13, 2005 | Gilead Sciences | low accrual | Enrollment / accrual |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | Phase 1 | terminated | Nov 19, 2012 | Gilead Sciences | Study was stopped due to insufficient efficacy and very slow accrual | Efficacy / futility |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Phase 1 / Phase 2 | withdrawn | Apr 12, 2010 | Gilead Sciences | No subjects enrolled | Enrollment / accrual |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse…(PLACARD) | Phase 1 / Phase 2 | withdrawn | Mar 13, 2019 | University College, London | There are insufficent funds to open the trial and start recruiting patients due to the impact of… | COVID-19 / pandemic |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With… | Phase 1 / Phase 2 | terminated | Apr 12, 2010 | Gilead Sciences | Study was terminated due to lack of efficacy | Efficacy / futility |
| NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Jul 2, 2015 | University of Washington | Accrual goal not met | Enrollment / accrual |
| NCT03618212 | MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the…(MYMO) | — | terminated | Aug 7, 2018 | Centre Hospitalier Universitaire de Nīmes | Departure of the project leader | Other (stated, no rule matched) |
| NCT04730505 | A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple…(MyHOPE™) | Phase 1 | terminated | Jan 29, 2021 | Celgene | Study faced multiple challenges and its launch was heavily impacted by COVID, which in turn has… | COVID-19 / pandemic |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | Phase 2 | terminated | Aug 16, 2018 | Weill Medical College of Cornell University | Lack of patient accruals. | Enrollment / accrual |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Sep 19, 2013 | M.D. Anderson Cancer Center | Per PI at time of CR | Other (stated, no rule matched) |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or… | Phase 1 | terminated | Mar 27, 2019 | The Lymphoma Academic Research Organisation | End of drug development | Other (stated, no rule matched) |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With… | Phase 1 | terminated | Nov 26, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell… | Phase 2 | terminated | Sep 15, 2011 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Oct 20, 2015 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons | Sponsor / business decision |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Phase 2 | terminated | Jun 6, 2017 | Columbia University | PI left institution | Investigator |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | Phase 2 | terminated | Mar 8, 2007 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic… | — | terminated | Oct 10, 2016 | Jonsson Comprehensive Cancer Center | withdrawn by sponsor | Other (stated, no rule matched) |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in… | Phase 3 | withdrawn | Feb 28, 2020 | Grupo Cooperativo de Hemopatías Malignas | incomplete recruitment | Enrollment / accrual |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants… | Phase 2 | terminated | Jun 26, 2018 | AbbVie | Following results of the primary progression-free survival analysis from Study NCT02755597,… | Sponsor / business decision |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete… | Phase 2 | terminated | May 1, 2014 | University of Arkansas | Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program. | Efficacy / futility |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing… | Phase 2 | terminated | Dec 23, 2014 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | new study | Other (stated, no rule matched) |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | Phase 1 / Phase 2 | terminated | May 2, 2016 | RedHill Biopharma Limited | Expiration of National Cancer Institute (NCI) funding of the study. | Funding |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | Phase 1 / Phase 2 | terminated | Sep 27, 2018 | Mundipharma-EDO GmbH | Sponsor decision based on adverse events limiting administration of higher doses required to… | Safety / toxicity |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | Phase 2 | terminated | May 11, 2018 | Swiss Cancer Institute | Feasibility (low patient accrual and financial reasons) | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 19, 2022source: clinicaltrials